CYP17A1 and prostate carcinoma: Binding of 1 to CYP17A1 was compared to that of abiraterone, a CYP17A1 inhibitor used pharmaceutically as a first-line treatment of prostate cancer that forms a type II Fe—N interaction as evidenced by a shift of the Soret peak to 424 nm.